Novartis Series D-3 Financing
In September 2011, our lawyers represented Novartis Bioventures in the $23,000,000 Series D-3 Financing for Tokai Pharmaceuticals, Inc. Tokai Pharmaceuticals, Inc., based out of Cambridge, Massachusetts, ia a biopharmaceutical company , focusing on developing new treatments for prostate cancer. Novartis Bioventures, is a venture fund also based in Cambridge, Massachusetts.
Posted on September 9, 2011
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.